> ## Content Index
> Fetch the complete content index at: https://nexi.fund/llms.txt
> Use this file to discover other available public pages before exploring further.

# T-Therapeutics Raises $133M to Put TCR Bispecifics in the Clinic
- URL: https://nexi.fund/t-therapeutics-133m-series-b-2026/
- Published: 2026-11-09T19:45:30.000Z
- Updated: 2026-11-09T19:45:30.000Z
- Description: Cambridge spinout T-Therapeutics raised $133 million before either lead drug reached a patient. The bet is on OpTiMus, a platform of fully human T-cell receptors aimed at targets inside the cell.
- Author: Nexi.fund Labs
- Tags: Biotech & Health, #mode-1, #hook-character, #track-A, #layout-classic-cascade

Theodora Harold has spent most of her career turning T-cell biology into drugs. On 5 November the company she leads, T-Therapeutics, closed an oversubscribed $133 million Series B. It is the largest cheque the Cambridge biotech has raised, and it arrived before either of its lead drugs had treated a single patient.

T-Therapeutics is a University of Cambridge spinout formed in 2022\. Its lead programmes are not ordinary antibodies. They are bispecific molecules that grab a cancer or immune cell with one arm and a T cell with the other, then let the immune system do the killing.

🎯

The money funds clinical proof-of-concept, not a launched product. Two preclinical programmes still have to clear first-in-human testing.  
  
The bet is on a platform, not a single molecule. OpTiMus supplies fully human T-cell receptors aimed at targets inside the cell.  
  
The risk sits exactly where the field has struggled: solid tumours, where T-cell engagers have been held back by a lack of usable targets. 

Ten T-cell engagers are already approved in the United States, almost all for blood cancers. The solid-tumour market is the part nobody has cracked.

## The cheque, the syndicate, and what it pays for

The round was co-led by Advent Life Sciences and British Business Bank, both new to the register. Johnson & Johnson Innovation, Samsara BioCapital, M-Ventures and Eli Lilly joined as new investors. Every major existing holder came back: Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF.

Representatives from Advent, British Business Bank, JJDC and Samsara take non-executive board seats. Four of the six new investors wanted a chair at the table, not only a line on the cap table.

$133M Series B, oversubscribed 

#### T-Therapeutics Series B

Announced 5 November 2026, co-led by Advent Life Sciences and British Business Bank. *Company release, 2026*

The company says the proceeds will carry both lead programmes into the clinic and through clinical proof-of-concept, and push earlier discovery work toward candidate selection. The round lands fewer than twelve months after a $32 million Series A extension that took the Series A total to $91 million. The original $59 million closed in 2023.

Alongside the cash, T-Therapeutics appointed Kirsty Crame as chief development officer. Crame was previously chief medical officer at Curatis, with earlier clinical roles at Medigene and Gadeta. Her brief is translational and clinical development, which is the shift from discovery to execution.

## OpTiMus and the targets hiding inside the cell

Most antibody drugs bind to proteins on the outside of a cell. That is a physical limit, and it rules out a large share of the proteins that drive cancer. T-cell receptors see a different layer: fragments of proteins from inside the cell, displayed on the surface by HLA molecules.

T-Therapeutics calls its platform OpTiMus. The company says it provides an unparalleled supply of fully human T-cell receptors, generated in engineered mice, then designed for high affinity and exquisite specificity against disease targets. The claim is that this opens validated but previously undruggable intracellular targets.

That is the whole investment case in one sentence. If the receptors work as advertised, the addressable target space widens well beyond what surface-binding antibodies can reach. If they do not, the company owns an expensive preclinical pipeline and a platform still looking for its first proof.

| Programme      | TTX-008                          | TTX-018                                    |
| -------------- | -------------------------------- | ------------------------------------------ |
| **Indication** | Solid tumours, pan-tumour driver | Autoimmune and chronic tissue inflammation |
| **Stage**      | Preclinical, IND-enabling        | Discovery                                  |
| **Format**     | TCR-CD3 bispecific               | TCR-CD3 bispecific                         |
| **Human data** | ✗ None yet                       | ✗ None yet                                 |

Company disclosures, November 2026\. Targets are undisclosed.

Both programmes are still preclinical. Neither has treated a patient. The oncology asset, TTX-008, is further along and in IND-enabling studies. The immunology asset, TTX-018, is less than a year behind it.

The two indications have little in common. Solid tumours are a target-discovery problem wrapped in a delivery problem. Autoimmune disease is a selectivity problem: the goal is to delete the pathogenic cells driving chronic inflammation without disabling the rest of the immune system. One platform is being asked to do both.

## A large cheque before the first patient

This is where the scepticism belongs. The round was oversubscribed, but it is a preclinical round. The company has disclosed little about its targets or development plans. TTX-008 is described only as aimed at an unspecified pan-tumour driver.

T-cell engagers have delivered clinical success in blood cancers. Solid tumours are a different problem: fewer clean surface targets, a hostile microenvironment, and a safety bar that punishes anything that also hits healthy tissue. Advent's Dominic Schmidt put the gap plainly. The modality has been held back in solid tumours by the lack of appropriate targets.

The comparison with the rest of this year's biotech tape is instructive. As we wrote in November, Oxford's [Alethio Therapeutics raised $90 million](https://nexi.fund/alethio-therapeutics-90m-series-a-2026/) for a rare blood-cancer programme. In October, [Nouscom raised $135 million](https://nexi.fund/nouscom-lynch-syndrome-cancer-vaccine-2026/) for a cancer interception vaccine. Both were large cheques for early bets. T-Therapeutics is asking for the same confidence one stage earlier.

Are the receptors specific enough to spare healthy tissue? Nobody outside the company can answer that yet. The first human data will. Until then, the preclinical package is the only evidence, and preclinical packages are where optimism is cheapest.

## Why big pharma keeps writing cheques

The syndicate is the part that deserves attention. Eli Lilly, Johnson & Johnson's venture arm, Sanofi Ventures and Germany's Merck KGaA venture arm M-Ventures are all on the register. These are not tourists. They are strategic investors who can read a preclinical package and price the risk.

The modality has momentum. Ten T-cell engagers have been approved by U.S. regulators, mostly for blood cancers, according to BioPharma Dive. The same outlet counts 29 licensing deals involving multi-pronged antibodies with China-based partners since the start of 2025\. Big pharma is buying the category faster than it is building it.

That matters for a company like T-Therapeutics. A strategic investor on the register is also a potential partner, acquirer or validation signal. The capital is not passive, and four new board seats show it.

That is the setup. A Cambridge platform company, a syndicate of strategic and specialist money, and a clinical question that will be settled in the first trials rather than in a pitch deck.

### What has to be true by 2028

🔮

**By the end of 2028, at least one of TTX-008 or TTX-018 will have reported initial human data, and the other will be in the clinic.**  
  
Probability: 55% — the company is funded through proof-of-concept and the oncology asset is already in IND-enabling studies, but the immunology programme starts further back and early-stage timelines slip. 

#### 🟢 Optimistic scenario (25%)

Both programmes enter the clinic and TTX-008 shows a clean early safety and response signal in a solid tumour. The platform is validated, and a partnership or follow-on round arrives on strong terms.  
  
**Consequences:** the target space claim gets external proof, and the valuation step-up is real. 

#### 🟡 Base scenario (50%)

TTX-008 reaches the clinic roughly on schedule and TTX-018 follows within a year. Early data are mixed but not disqualifying, and the company raises again to fund expansion.  
  
**Consequences:** the story stays alive, but the platform premium is deferred by another cycle. 

#### 🔴 Pessimistic scenario (25%)

A safety or specificity issue emerges in preclinical or first-in-human work, or the undisclosed target fails to translate into a solid-tumour response.  
  
**Consequences:** the next round is flat or down, and the platform's broader claims get repriced. 

The $133 million does not answer the science question. It buys the company the right to ask it in humans. For investors, that is the whole trade: a platform with a wider target space, priced before the first data point.

[ T-Therapeutics closes an oversubscribed $133 million Series B The company release with the full syndicate, use of proceeds and the appointment of Kirsty Crame as chief development officer. T-Therapeutics ](https://t-therapeutics.com/t-therapeutics-announces-oversubscribed-133-million-series-b-financing-to-achieve-clinical-proof-of-concept-for-first-in-class-tcr-bispecific-therapies-in-cancer-and-autoimmune-disease/?ref=nexi.fund) 

Primary source for the round mechanics and the two lead programmes.

[ T-Therapeutics reloads with a $133M megaround for bispecifics Independent reporting on the pipeline, the undisclosed targets, and the wider T-cell engager field. BioPharma Dive ](https://www.biopharmadive.com/news/t-therapeutics-series-b-tces-bispecifics-cancer-autoimmune/873786/?ref=nexi.fund) 

Source for the ten approved engagers and the China licensing count.

[ T-Therapeutics raises $133M with Big Pharma backers in tow Programme stages, the Series A history and the company's move from discovery into development. Fierce Biotech ](https://www.fiercebiotech.com/biotech/t-therapeutics-raises-133m-series-b-big-pharma-backers-tow?ref=nexi.fund) 

Useful for the IND-enabling timeline and the earlier round sizes.

[ British biotech pours $133M into the pot for bispecifics Context on the T-cell engager race and the Cambridge company's position inside it. BioSpace ](https://www.biospace.com/drug-development/t-time-british-biotech-pours-133m-into-the-pot-for-bispecifics?ref=nexi.fund) 

Adds the strategic-investor read on the round.

[ T-Therapeutics raises $133M for TCR bispecifics A European funding-desk view of the round, the returning investors and the preclinical risk. Sesamers ](https://www.sesamers.com/funding/t-therapeutics-raises-133m-series-b-tcr-bispecifics?ref=nexi.fund) 

Independent check on the euro value and the board composition.